ICoLA 2019

Date	Time	Room	Session/Title	Presentation Time	Presentation Title	Role
Sep. 5 (Thu.)	16:00-17:30	Room 5	Symposium 2 / Reappraisal of Immune Cells in Cardiovascular Disease	16:20-16:40	Macrophage Immunometabolism in Heart	Chairperson
Sep. 5 (Thu.)	16:00-17:30	Room 5	Symposium 2 / Reappraisal of Immune Cells in Cardiovascular Disease	16:20-16:40	Macrophage Immunometabolism in Heart	Chairperson

LUNCHEON SYMPOSIUM 1: Sep. 6 (Fri.)
12:10~13:10; Room 1

more

Chairperson Cheol Ho Kim (Seoul National University, Korea)

12:10-12:30	Optimizing Risk Reduction Strategies in Patients with Diabetes and Atherosclerotic Cardiovascular Disease Robert S. Rosenson (The Mount Sinai Hospital in New York, USA)	Abstract
12:30-12:50	The Evidence of Using Metformin as a Treatment for Patients with Type 2 Diabetes Hye Soon Kim (Keimyung University, Korea)	Abstract

LUNCHEON SYMPOSIUM 2: Sep. 6 (Fri.)
12:10~13:10; Room 2

more

Chairperson Hyun Chul Lee (Yonsei University, Korea)

12:10-12:40

The Additional Benefits of Anagliptin Beyond Glycemic Control Jun Hwa Hong (Eulji University, Korea)

Abstract

LUNCHEON SYMPOSIUM 3: Sep. 6 (Fri.)
12:10~13:10; Room 3

more

Chairperson Kwang-Won Kim (Gachon University, Korea)

12:10-12:40

Additional Benefits of Rosuvastatin/Ezetimibe Combination Therapy Yong-ho Lee (Yonsei University, Korea)

Abstract

LUNCHEON SYMPOSIUM 4: Sep. 6 (Fri.)
12:10~13:10; Room 4

more

Chairperson Ho Young Son (The Catholic University of Korea, Korea)

12:10-12:30	Advantages of Rosuvastatin and Ezetimibe Combination Treatment Moo-Yong Rhee (Dongguk University, Korea)	Abstract
12:30-12:50	Evidence-Based Approach for Ideal Hypertension Management Soon Jun Hong (Korea University, Korea)

LUNCHEON SYMPOSIUM 5: Sep. 7 (Sat.)
12:10~13:10; Room 1

more

Chairperson Hong Kyu Lee (Eulji University, Korea)

12:10-12:30	See the Unseen in Recent Cardiorenal Outcome Trials of T2DM Treatments Soo Lim (Seoul National University, Korea)	Abstract
12:30-12:50	Treatment Approach for Type 2 Diabetes Considering the Stable Glycemic Control So Hun Kim (Inha University, Korea)	Abstract

LUNCHEON SYMPOSIUM 6: Sep. 7 (Sat.)
12:10~13:10; Room 2

more

Chairperson Dong Soo Kim (Inje University, Korea)

12:10-12:50	Current and Future Lipid Treatment through Recent Key Outcomes Anselm K. Gitt (Ludwigshafen University, Germany)	Abstract
12:50-13:10	Discussion

LUNCHEON SYMPOSIUM 7 The Need for Additional Glucose-lowering Therapies with Proven Long-term Cardiovascular Safety Profiles: Sep. 7 (Sat.)
12:10~13:10; Room 3

more

Chairperson Yeong Gil Choi (Kyung Hee University, Korea)

12:10-12:30	The Impact of Empagliflozin beyond Glucose Control : from Mechanism to Outcome Stefano Del Prato (University of Pisa, Italy)
12:30-12:50	Comprehensive Data from Empagliflozin : How These Results Translate into Routine Clinical Practice? Kausik Ray (Imperial College London, UK)	Abstract

LUNCHEON SYMPOSIUM 8: Sep. 7 (Sat.)
12:10~13:10; Room 4

more

Chairperson Kyoo-Rok Han (Hallym University,Korea)

12:10-12:40

Recent Updates in Hypertension Goals: What Does The Physician Need to Know? Sanjay Rajagopalan (Case Western Reserve University, USA)

Abstract

LUNCHEON SYMPOSIUM 1 [Organon]: Sep.10(Fri.)

Chairperson Hong Kyu Lee (Seoul National University, Korea)

12:05-12:25	Insight for T2DM and/or metabolism syndrome with complication to manage dyslipidemia Seung-Hwan Lee (The Catholic University of Korea, Korea)
12:25-12:35	Discussion

LUNCHEON SYMPOSIUM 2 [Amgen]: Sep.10(Fri.)

Chairperson Hyun Ho Shin (Asan Chungmu Hospital, Korea)

12:05-12:25	Familial hypercholesterolemia: diagnosis and management Chan Joo Lee (Yonsei University, Korea)
12:25-12:35	Discussion

LUNCHEON SYMPOSIUM 3 [Viatris]: Sep.10(Fri.)

Chairperson Donghoon Choi (Yonsei University, Korea)

12:05-12:25	What are the optimal options of dyslipidemia management for your patients? based on treatment continuum Hyun Jae Kang (Seoul National University, Korea)
12:25-12:35	Discussion

LUNCHEON SYMPOSIUM 4 [Yuhan]: Sep.10(Fri.)

Chairperson Shung Chull Chae (Kyungpook National University, Korea)

12:05-12:25	The needs for combination therapy (Ezetimibe and Statin) Hyo-In Choi (Sungkyunkwan University, Korea)
12:25-12:35	Discussion

LUNCHEON SYMPOSIUM 5 [Daewoong]: Sep.11(Sat.)

Chairperson Sang Hong Baek (The Catholic University of Korea, Korea)

12:10-12:30	Lower is better & combination is better [Ezetimibe+Rosuvastatin] Soo Heon Kwak (Seoul National University, Korea)
12:30-12:40	Discussion

LUNCHEON SYMPOSIUM 6 [JW Pharmaceutical]: Sep.11(Sat.)

Chairperson Hyun Chul Lee (Yonsei University, Korea)

12:10-12:30	Cutting edge care of Pitavastatin with Ezetimibe combination therapy Ki Hoon Han (University of Ulsan, Korea)
12:30-12:40	DIscussion

LUNCHEON SYMPOSIUM 7 [Hanmi]: Sep.11(Sat.)

Chairperson Jeong Euy Park (Sungkyunkwan University, Korea)

12:10-12:30	Why should we consider Rosuvastatin + Ezetimibe fixed dose combination? Jung-Kyu Han (Seoul National University, Korea)
12:30-12:40	Discussion

LUNCHEON SYMPOSIUM 8 [HK. inno.N]: Sep.11(Sat.)

Chairperson Jeong Taek Woo (Kyung Hee University, Korea)

12:10-12:30	Controlling dyslipidemia and CV risk with Atorvastatin and Ezetimibe Soon Jun Hong (Korea University, Korea)
12:30-12:40	Discussion

Luncheon Symposia